Lurasidone filed with EMA for schizophrenia
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has said that the European Medicines Agency (EMA) has accepted for review Takeda's marketing authorisation application (MAA) for the oral atypical antipsychotic, lurasidone hydrochloride, for the treatment of schizophrenia.The once-daily medication was discovered and developed by DSP and licensed to Takeda in March 2011, granting the latter exclusive commercialisation rights for lurasidone in 26 EU member states (excluding the UK), and Switzerland, Norway, Turkey and Russia. (The companies undertook joint responsibility for the drug's development.)